Mode
Text Size
Log in / Sign up

Observational genomic study of over 500 Indian breast tumors identifies novel mutations and subtypes

Observational genomic study of over 500 Indian breast tumors identifies novel mutations and subtypes
Photo by sujatha karantha / Unsplash
Key Takeaway
Consider genomic insights from Indian breast tumors as descriptive biology, not proven clinical guidance.

This observational study performed whole-genome and transcriptome analysis on over 500 clinically annotated, treatment-naive breast tumors from India. No specific intervention, comparator, or primary outcome was reported. The research aimed to characterize the genomic landscape of this population.

The analysis identified novel significantly mutated genes under positive selection and uncovered recurrent copy number alterations driving lipid metabolic reprogramming. Mutational processes were dominated by DNA repair deficiency, APOBEC activity, and genome instability. The study revealed three genomic features significantly associated with poor post-surgical recurrence-free survival and distinct intrinsic subtypes with divergent immune landscapes. A novel transcriptomic signature capturing a HER2-like transcriptional state within triple-negative breast cancer patients was also found. The research revealed clinically actionable germline and somatic alterations with high significance.

Safety and tolerability data were not reported. Key limitations, including specific methodological constraints or potential biases, were not detailed in the provided information. The study's practice relevance is framed as providing critical insights into tumor biology and advancing precision oncology, but its observational nature precludes causal claims about treatment effects. The findings are descriptive and require validation in prospective clinical settings.

Study Details

EvidenceLevel 5
PublishedMar 2026
View Original Abstract ↓
Breast cancer remains the leading cause of cancer-related mortality among women globally, yet South Asian populations are critically underrepresented in genomic studies. Here, we present whole-genome and transcriptome analyses of over 500 treatment-naive, clinically annotated breast tumors from India, representing the first large-scale integrative omics characterization of this population. In addition to established drivers, we identify novel significantly mutated genes, including ISM2, TERF2, and DHRSX, under positive selection, along with previously unreported potentially pathogenic somatic variants. Notably, the distribution of key hotspot mutations appears shaped by immune escape pressures. We uncover recurrent copy number alterations driving lipid metabolic reprogramming (e.g., NCEH1 and PLD1 amplifications) and complex structural events, including IKZF3 promoter hijacking leading to ERBB2 overexpression and TTC28-associated genomic instability--findings not previously described in breast cancer. Mutational processes are dominated by DNA repair deficiency, APOBEC activity, and genome instability. We identify three genomic features significantly associated with poor post-surgical recurrence-free survival. Transcriptomic profiling reveals distinct intrinsic subtypes with divergent immune landscapes, including a high-risk HER2-androgenic cluster with the worst outcomes. Additionally, we find a novel transcriptomic signature that robustly captures a HER2-like transcriptional state within triple-negative breast cancer patients - with major implications for TNBC treatment. Finally, clinically actionable germline and somatic alterations are revealed with high significance, highlighting opportunities for therapeutic repurposing. Together, the study establishes a comprehensive molecular atlas of breast cancer in an underrepresented population, providing critical insights into tumour biology and advancing precision oncology.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.